Loading...
•
Sep 30, 2023
Arcellx Q3 2023 Earnings Report
Reported financial results for the third quarter of 2023 and provided recent business highlights.
Key Takeaways
Arcellx reported collaboration revenue of $15.0 million for Q3 2023, driven by the Kite Pharma agreement. The company's cash, cash equivalents, and marketable securities totaled $482.7 million as of September 30, 2023, expected to fund operations into 2026. Net loss for the quarter was $39.3 million.
Announced oral presentation at ASH in December, highlighting CART-ddBCMA trial data with median follow-up of 22 months.
CART-ddBCMA continues to be well-tolerated with no observed delayed neurotoxicities or parkinsonian symptoms.
Resumed enrollment in iMMagine-1 study, advancing the program towards commercial availability.
New clinical data from CART-ddBCMA Phase 1 trial will be presented at the ASH Annual Meeting.
Forward Guidance
Arcellx anticipates that its cash, cash equivalents, and marketable securities will fund its operations into 2026.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...